ClinicalTrials.gg
RecruitingNCT05949567Cysto-positionUpdated Apr 17, 2026

Does Position Influence the Diagnosis of Detrusor Overactivity in a Neurological Population

An interventional study of urodynamic exam in sitting and lying position in Urodynamic Exam and Neurologic Disorder, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-17.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

ICS (International Continence Society) recommendations published in 2017 recommend performing urodynamic examinations in the sitting or standing position. These recommendations are based on a review of the literature published in 2008, which has several limitations: heterogeneous populations, old and non-harmonized techniques, and very few neurological patients. It seems appropriate to focus on neurological patients and to examine the influence of position on the detection of detrusor overactivity in these patients.

The point here is to reexamine the ICS recommendations, which are not designed for neurological patients. Indeed, many patients suffering from Multiple Sclerosis (MS) or Parkinson's disease are unable to sit or stand for the duration of the urodynamic examination. The investigators would like to assess whether exploring sphincter disorders in the supine position is still interpretable.

This would enable us to define ICS good practice recommendations for a neurological population.

Read the detailed description

1st consultation (selection - D-15):

  • Targeted questioning of disorders, completion of USP self-questionnaire, and UPDRS or EDSS scales as part of care.
  • Verification of ultrasound results (for men).
  • Schedule Urodynamic Assessment as part of treatment.
  • Verification of eligibility criteria
  • Partial information of the patient (or relative/guardian/guardian if applicable) to limit bias, and a period of reflection prior to the urodynamic test to collect consent.

On the day of the Urodynamic Assessment (D0):

  • Written, free and informed consent.
  • Data collection by a physician trained in the study,
  • Randomization of patient to determine starting position (lying or sitting) for urodynamic assessment (via CleanWeb).
  • Urodynamic assessment according to ICS recommendations, with constant filling speed over the 2 fillings (50 ml/min), water filling - Laborie machine - T-Doc system in both positions in the order defined by randomization, and printout of curves.
  • Entry of socio-demographic data.
  • Curves reread by a doctor who had not performed the examination and who did not know the patient or the starting position (single blind).
  • Completion of the paper file by the physician reading the curves, with the following data for position 1 and position 2:
  • Volume at B1 and B3 (in ml)
  • Basal bladder pressure (cm / H2O)
  • Occurrence of CNID or mictional reflex arc (diagnosis of detrusor overactivity)
  • Volume of leakage or 1st NIDC (Uninhibited Detrusor Contraction) (ml) or
  • Bladder pressure at leakage (cm / H2O)
  • Maximum bladder pressure (cm / H2O)
  • Paper data entry on Excel database by a trained investigator declared on the study
02

Conditions studied

  • Urodynamic Exam
  • Neurologic Disorder

Keywords

  • Urodynamic exam
  • detrusor overactivity
  • positon
03

In context

Nervous System Diseases

757 studies on the registry are indexed under Nervous System Diseases; 218 are open to participants now.

This study's planned enrollment of 160 is above the median of 55 across 495 interventional studies indexed under Nervous System Diseases.

Browse Nervous System Diseases studies →

Lead sponsor

Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,592 studies on the registry; 1,033 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with MS or neurologically confirmed Parkinson's disease, with indication for urodynamic assessment - 1st assessment
  • Clinical overactive bladder syndrome with USP overactive bladder sub-score > or = 4 - Age ≥18 years
  • In men: no prostatic hypertrophy on ultrasonography
  • In women: no stress urinary incontinence (SUI); USP SUI subscore ≤ 2
  • Affiliated with a social security scheme (excluding AME).
  • Free and informed written consent

Exclusion criteria

Exclusion Criteria:

  • Opposition to the performance of a Urodynamic exam as part of treatment
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    Lying position first - then sitting position

    Other: urodynamic exam in sitting and lying position

  • Experimental
    Sitting position first - then lying position

    Other: urodynamic exam in sitting and lying position

Interventions

  • Otherurodynamic exam in sitting and lying position

    Urodynamic exam with 1st filling in sitting or lying position. Then , during the same procedure, a second filling in the opposite position of the 1st filling (lying or sitting)

06

What researchers measure

Primary outcomes

  1. concordance diagnosis of detrusor overactivity between lying and sitting position

    Measurement concordance of detrusor pressures using the intraclass correlation coefficient statistic

    Time frame: 24 months

Secondary outcomes

  1. position influence on the overactive detrusor gravity between the 2 positions

    Measurement of the concordance of detrusor overactivity diagnostic gravities during urodynamic assessments, between those performed in the supine position and those performed in the seated position. Concordance will be assessed using Cohen's Kappa statistic.

    Time frame: 24 months

  2. Evaluation of the diagnosis quality of the detrusor overactivity between the 2 position

    Measurement of the diagnostic quality of urodynamic testing performed in the supine position in neurological patients to detect detrusor activity, with the seated position being the gold standard: estimation of sensitivity and specificity.

    Time frame: 24 months

  3. comparison of the distribution of detrusor overactivity diagnoses according to position.

    Measurement of the association between position during urodynamic assessment and diagnosis of detrusor overactivity: comparison of the distribution of diagnoses of detrusor overactivity according to position.

    Time frame: 24 months

07

Study locations

1 of 1 sites recruiting
  • Physical and Rehabilitation Medicine Pitié Salpêtrière Hospital
    Paris, France 75013, France
    Recruiting
    • Bertrand M PICHON, MD · ContactBertrand.pichon@aphp.fr · 142161047
    • Helene Ms Robert, MD · ContactHelene.robert@aphp.fr · 142161137
    • Matthieu M GRASLAND, MD · Sub investigator
    • Bertrand M PICHON, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — Data are available upon reasonable request The procedures carried out with the French data privacy authority (CNIL, National Commission for Computing and Liberties) do not provide for the transmission of the database, nor do the information and consent documents signed by the patients. Consultation by the editorial board or interested researchers of individual participant data that underlie the results reported in the article after deidentification may nevertheless be considered, subject to prior determination of the terms and conditions of such consultation and in respect for compliance with the applicable regulations.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Beginning 3 months and ending 3 years following article publication. Requests out of these time frame can also be submitted to the sponsor

Access criteria: Researchers who provide a methodologically sound proposal.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05949567
Responsible party
Sponsor
First posted
Jul 18, 2023
Start date
Apr 2, 2024
Primary completion
Apr 2, 2027 (estimated)
Completion
Apr 2, 2027 (estimated)
Last update
Apr 17, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion